journal
MENU ▼
Read by QxMD icon Read
search

CNS Spectrums

journal
https://www.readbyqxmd.com/read/28631584/clinical-characterization-of-italian-suicide-attempters-with-bipolar-disorder
#1
Bernardo Dell'Osso, Matteo Vismara, Cristina Dobrea, Laura Cremaschi, Benedetta Grancini, Chiara Arici, Beatrice Benatti, Massimiliano Buoli, Terence A Ketter, A Carlo Altamura
Introduction Bipolar disorder (BD) is a chronic, highly disabling condition associated with psychiatric/medical comorbidity and substantive morbidity, mortality, and suicide risks. In prior reports, varying parameters have been associated with suicide risk. OBJECTIVES: To evaluate sociodemographic and clinical variables characterizing Italian individuals with BD with versus without prior suicide attempt (PSA). METHODS: A sample of 362 Italian patients categorized as BD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM IV-TR) was assessed and divided in 2 subgroups: with and without PSA...
June 20, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28625204/effect-of-aripiprazole-lauroxil-in-patients-with-acute-schizophrenia-as-assessed-by-the-positive-and-negative-syndrome-scale-supportive-analyses-from-a-phase-3-study
#2
Leslie Citrome, Robert Risinger, Andrew J Cutler, Yangchun Du, Jacqueline Zummo, Henry A Nasrallah, Bernard L Silverman
OBJECTIVE: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic that was evaluated for the treatment of schizophrenia in a randomized, placebo-controlled, Phase 3 study. Here, we present exploratory analyses of supportive efficacy endpoints. METHODS: Patients experiencing an acute exacerbation of schizophrenia received AL 441 mg intramuscularly (IM), AL 882 mg IM, or matching placebo IM monthly. Supportive endpoints included changes from baseline at subsequent time points in Clinical Global Impression-Severity (CGI-S) scale score; Positive and Negative Syndrome Scale (PANSS) Total score; PANSS Positive, Negative, and General Psychopathology subscale scores; PANSS Marder factors (post hoc); and PANSS responder rate...
June 19, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28625201/a-perspective-on-the-editorial-by-ken-gillman-much-ado-about-nothing-monoamine-oxidase-inhibitors-drug-interactions-and-dietary-tyramine
#3
https://www.readbyqxmd.com/read/28535835/a-biopsychosocial-evaluation-of-the-risk-for-suicide-in-schizophrenia
#4
Nuwan C Hettige, Ali Bani-Fatemi, Isaac Sakinofsky, Vincenzo De Luca
The risk of suicide is greatly increased in individuals with schizophrenia. Previous research has identified several potential risk factors for suicidal behavior in schizophrenia, although their ability to independently predict suicide is limited. The objective of this review was to systematically analyze and identify the interaction between the proposed risk factors in the literature that may predict suicidal behavior in schizophrenia. Articles that explored suicidal behavior and suicide risk in schizophrenia that were published between 1980 and August of 2015, indexed in PubMed, MEDLINE, and Scopus were systematically reviewed...
May 24, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28521846/measures-of-suicidality-in-phase-3-clinical-trials-of-levomilnacipran-er-in-adults-with-major-depressive-disorder
#5
Michael E Thase, Carl Gommoll, Changzheng Chen, Kenneth Kramer, Arif Khan, Suresh Durgam
OBJECTIVE: To evaluate the effects of levomilnacipran extended-release (ER) on suicidal ideation and behavior in adults with major depressive disorder (MDD). METHODS: Post hoc analyses were conducted in patients from 4 randomized, double-blind, placebo-controlled trials and a long-term, open-label extension study of levomilnacipran ER (40-120 mg/d) in adults with MDD. Analyses included incidence of suicide-related treatment-emergent adverse events (TEAEs); incidence of Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation (score=1-5) and behavior (score=6-10); percent of patients who shifted from no C-SSRS suicidal ideation/behavior at baseline to suicidal ideation during treatment (worsened from score=0 to score=1-5), or vice-versa (improved from score=1-5 to score=0)...
May 19, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28514974/additional-thoughts-on-teaching-and-prescribing-maois
#6
S Shalom Feinberg
No abstract text is available yet for this article.
May 18, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28490392/a-systematic-review-of-the-heritability-of-specific-psychopathic-traits-using-hare-s-two-factor-model-of-psychopathy
#7
Sapna Dhanani, Veena Kumari, Basant K Puri, Ian Treasaden, Susan Young, Piyal Sen
BACKGROUND: There have been no systematic reviews that investigated the heritability of the two-factor model of psychopathy: interpersonal-affective and behavioral. Our review aimed, first, to examine the heritability of general psychopathic traits and, second, if genetic influences were suggested, to determine the heritability of various traits related to the interpersonal-affective and behavioral factors of psychopathy. METHOD: A systematic literature search was conducted using articles from the PsycINFO, Embase, Global Health, Medline, PubMed, Web of Science, and Scopus databases (January of 1980 to December of 2015) in order to identify eligible literature that reported on the heritability of psychopathy-related traits...
May 11, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28487007/unpacking-the-role-of-self-reported-compulsivity-and-impulsivity-in-obsessive-compulsive-disorder
#8
Luisa Prochazkova, Linden Parkes, Andrew Dawson, George Youssef, Gabriela M Ferreira, Valentina Lorenzetti, Rebecca A Segrave, Leonardo F Fontenelle, Murat Yücel
OBJECTIVE: We aimed to determine whether individuals with obsessive-compulsive disorder (OCD) and demographically matched healthy individuals can be clustered into distinct clinical subtypes based on dimensional measures of their self-reported compulsivity (OBQ-44 and IUS-12) and impulsivity (UPPS-P). METHODS: Participants (n=217) were 103 patients with a clinical diagnosis of OCD; 79 individuals from the community who were "OCD-likely" according to self-report (Obsessive-Compulsive Inventory-Revised scores equal or greater than 21); and 35 healthy controls...
May 10, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28478771/evaluation-of-the-long-term-safety-and-tolerability-of-cariprazine-in-patients-with-schizophrenia-results-from-a-1-year-open-label-study
#9
Andrew J Cutler, Suresh Durgam, Yao Wang, Raffaele Migliore, Kaifeng Lu, István Laszlovszky, György Németh
OBJECTIVE: Cariprazine, a dopamine D3/D2 partial agonist atypical antipsychotic with preferential binding to D3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. The efficacy and safety of cariprazine was established in three randomized, double-blind, placebo-controlled, 6-week trials in patients with acute exacerbation of schizophrenia. This 53-week study evaluated the long-term safety and tolerability of cariprazine in patients with schizophrenia...
May 8, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28463099/remission-and-recovery-associated-with-lurasidone-in-the-treatment-of-major-depressive-disorder-with-subthreshold-hypomanic-symptoms-mixed-features-post-hoc-analysis-of-a-randomized-placebo-controlled-study-with-longer-term-extension-corrigendum
#10
Joseph F Goldberg, Daisy Ng-Mak, Cynthia Siu, Chien-Chia Chuang, Krithika Rajagopalan, Antony Loebel
No abstract text is available yet for this article.
May 2, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28420451/what-leads-to-high-antipsychotic-dosing-in-forensic-patients-with-schizophrenia
#11
Branimir Margetić, Branka Aukst Margetić, Dragutin Ivanec, Tija Žarković Palijan
Earlier findings suggest that forensic schizophrenia patients are treated with higher doses of antipsychotics. This practice-based specificity is insufficiently studied, and clinicians' motives regarding this practice remain poorly understood. In this editorial, the authors provide their data on treatment of forensic schizophrenia patients and identify characteristics of psychopathology and previous types of behaviors, including suicidal attempts, as potential reasons for the practice. They also emphasize that "these previous acts" often took place years ago, and suggest that current or recent aggression is unlikely the main reason for dosing, but rather the clinicians' intention to maintain "must remain unaggressive" condition...
April 19, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28376938/does-treating-hearing-loss-prevent-or-slow-the-progress-of-dementia-hearing-is-not-all-in-the-ears-but-who-s-listening
#12
Stephen M Stahl
Since hearing loss is strongly linked to cognitive decline, treating hearing impairment may have the potential to prevent the onset or slow the progress of dementia.
April 5, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28571592/hyperkinesia-in-ancient-china-perspectives-and-prescriptions
#13
Jia Liu, Lu-Ning Wang
No abstract text is available yet for this article.
June 2017: CNS Spectrums
https://www.readbyqxmd.com/read/26863160/deep-brain-stimulation-for-bipolar-disorder-review-and-outlook
#14
Sabrina M Gippert, Christina Switala, Bettina H Bewernick, Sarah Kayser, Alena Bräuer, Volker A Coenen, Thomas E Schlaepfer
Research on deep brain stimulation (DBS) for treatment-resistant psychiatric disorders has established preliminary efficacy signals for treatment-resistant depression. There are only few studies on DBS that included patients suffering from bipolar disorder. This article gives an overview of these studies concerning DBS targets, antidepressant efficacy, and the occurrence of manic/hypomanic symptoms under stimulation. First, promising results show that all patients experienced significant improvement in depressive symptomatology...
June 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28462772/mixed-features-in-major-depressive-disorder-diagnoses-and-treatments
#15
Trisha Suppes, Michael Ostacher
For the first time in 20 years, the American Psychiatric Association (APA) updated the psychiatric diagnostic system for mood disorders in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Perhaps one of the most notable changes in the DSM-5 was the recognition of the possibility of mixed symptoms in major depression and related disorders (MDD). While MDD and bipolar and related disorders are now represented by 2 distinct chapters, the addition of a mixed features specifier to MDD represents a structural bridge between bipolar and major depression disorders, and formally recognizes the possibility of a mix of hypomania and depressive symptoms in someone who has never experienced discrete episodes of hypomania or mania...
April 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28421980/guidelines-for-the-recognition-and-management-of-mixed-depression
#16
Stephen M Stahl, Debbi A Morrissette, Gianni Faedda, Maurizio Fava, Joseph F Goldberg, Paul E Keck, Yena Lee, Gin Malhi, Ciro Marangoni, Susan L McElroy, Michael Ostacher, Joshua D Rosenblat, Eva Solé, Trisha Suppes, Minoru Takeshima, Michael E Thase, Eduard Vieta, Allan Young, Mark Zimmerman, Roger S McIntyre
A significant minority of people presenting with a major depressive episode (MDE) experience co-occurring subsyndromal hypo/manic symptoms. As this presentation may have important prognostic and treatment implications, the DSM-5 codified a new nosological entity, the "mixed features specifier," referring to individuals meeting threshold criteria for an MDE and subthreshold symptoms of (hypo)mania or to individuals with syndromal mania and subthreshold depressive symptoms. The mixed features specifier adds to a growing list of monikers that have been put forward to describe phenotypes characterized by the admixture of depressive and hypomanic symptoms (e...
April 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28416033/pharmacological-treatment-of-mixed-states
#17
Alessandro Cuomo, Viktoriya L Nikolova, Nefize Yalin, Danilo Arnone, Andrea Fagiolini, Allan H Young
Mixed states in bipolar disorder have been neglected, and the data concerning treatment of these conditions have been relatively obscure. To address this, we systematically reviewed published pharmacological treatment data for "mixed states/episodes" in mood disorders, including "with mixed features" in DSM-5. We searched PubMed, MEDLINE, The Cochrane Library, clinicaltrials.gov, and controlled-trials.com (with different combinations of the following keywords: "mixed states/features," "bipolar," "depressive symptoms/bipolar depression," "manic symptoms," "treatment," "DSM-5") through to October 2016...
April 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28357969/lurasidone-for-major-depressive-disorder-with-mixed-features-and-anxiety-a-post-hoc-analysis-of-a-randomized-placebo-controlled-study
#18
Joyce Tsai, Michael E Thase, Yongcai Mao, Daisy Ng-Mak, Andrei Pikalov, Antony Loebel
OBJECTIVE: The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating patients with major depressive disorder (MDD) with mixed features who present with mild and moderate-to-severe levels of anxiety. METHODS: The data in this analysis were derived from a study of patients meeting the DSM-IV-TR criteria for unipolar MDD, with a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26, presenting with two or three protocol-defined manic symptoms, who were randomized to 6 weeks of double-blind treatment with either lurasidone 20-60 mg/day (n=109) or placebo (n=100)...
April 2017: CNS Spectrums
https://www.readbyqxmd.com/read/27629159/treatment-recommendations-for-dsm-5-defined-mixed-features
#19
Joshua D Rosenblat, Roger S McIntyre
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) mixed features specifier provides a less restrictive definition of mixed mood states, compared to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), including mood episodes that manifest with subthreshold symptoms of the opposite mood state. A limited number of studies have assessed the efficacy of treatments specifically for DSM-5-defined mixed features in mood disorders. As such, there is currently an inadequate amount of data to appropriately inform evidence-based treatment guidelines of DSM-5 defined mixed features...
April 2017: CNS Spectrums
https://www.readbyqxmd.com/read/27618746/treatment-of-mixed-features-in-bipolar-disorder
#20
Joshua D Rosenblat, Roger S McIntyre
Mood episodes with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)-defined mixed features are highly prevalent in bipolar disorder (BD), affecting ~40% of patients during the course of illness. Mixed states are associated with poorer clinical outcomes, greater treatment resistance, higher rates of comorbidity, more frequent mood episodes, and increased rates of suicide. The objectives of the current review are to identify, summarize, and synthesize studies assessing the efficacy of treatments specifically for BD I and II mood episodes (ie, including manic, hypomanic, and major depressive episodes) with DSM-5-defined mixed features...
April 2017: CNS Spectrums
journal
journal
32687
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"